Valeant Pharmaceuticals International Inc (NYSE:VRX) Institutional Investor Sentiment Is 0.99

January 13, 2018 - By Adrian Erickson

 Valeant Pharmaceuticals International Inc (NYSE:VRX) Institutional Investor Sentiment Is 0.99

Sentiment for Valeant Pharmaceuticals International Inc (NYSE:VRX)

Valeant Pharmaceuticals International Inc (NYSE:VRX) institutional sentiment decreased to 0.99 in Q3 2017. Its down -0.09, from 1.08 in 2017Q2. The ratio dropped, as 110 funds opened new or increased holdings, while 111 sold and decreased positions in Valeant Pharmaceuticals International Inc. The funds in our partner’s database now possess: 169.87 million shares, down from 171.89 million shares in 2017Q2. Also, the number of funds holding Valeant Pharmaceuticals International Inc in their top 10 holdings was flat from 6 to 6 for the same number . Sold All: 43 Reduced: 68 Increased: 83 New Position: 27.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $8.30 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 6.08 P/E ratio. Diversified Products.

The stock increased 0.13% or $0.03 during the last trading session, reaching $23.84. About 10.21M shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has declined 48.51% since January 13, 2017 and is downtrending. It has underperformed by 65.21% the S&P500.

Analysts await Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report earnings on February, 27. They expect $0.97 EPS, down 23.02 % or $0.29 from last year’s $1.26 per share. VRX’s profit will be $337.83 million for 6.14 P/E if the $0.97 EPS becomes a reality. After $1.04 actual EPS reported by Valeant Pharmaceuticals International, Inc. for the previous quarter, Wall Street now forecasts -6.73 % negative EPS growth.

Chou Associates Management Inc. holds 15.29% of its portfolio in Valeant Pharmaceuticals International, Inc. for 3.05 million shares. Beach Point Capital Management Lp owns 1.09 million shares or 3.62% of their US portfolio. Moreover, Tb Alternative Assets Ltd. has 3.06% invested in the company for 593,200 shares. The California-based Valueact Holdings L.P. has invested 2.59% in the stock. Academy Capital Management Inc Tx, a Texas-based fund reported 629,003 shares.#img1#

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Ratings analysis reveals 22% of Valeant Pharmaceuticals Intl’s analysts are positive. Out of 27 Wall Street analysts rating Valeant Pharmaceuticals Intl, 6 give it “Buy”, 5 “Sell” rating, while 16 recommend “Hold”. The lowest target is $7.0 while the high is $310. The stock’s average target of $51.33 is 115.31% above today’s ($23.84) share price. VRX was included in 148 notes of analysts from July 21, 2015. H.C. Wainwright maintained the stock with “Hold” rating in Friday, November 3 report. The firm has “Neutral” rating by Goldman Sachs given on Monday, November 2. UBS maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Friday, October 30 with “Buy” rating. The firm has “Hold” rating given on Friday, June 16 by RBC Capital Markets. Piper Jaffray maintained it with “Sell” rating and $1000 target in Wednesday, July 12 report. The rating was maintained by Jefferies on Monday, October 16 with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, July 28. The firm has “Market Perform” rating given on Thursday, May 11 by BMO Capital Markets. Piper Jaffray maintained Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Wednesday, August 9 with “Sell” rating. The firm earned “Overweight” rating on Wednesday, November 11 by JP Morgan.

More notable recent Valeant Pharmaceuticals International, Inc. (NYSE:VRX) news were published by: which released: “Valeant’s ‘Significant Seven’ Aren’t Quite Magnificent: Gadfly” on January 10, 2018, also with their article: “Be Extremely Careful With Valeant Pharmaceuticals Intl Inc Stock Price” published on December 21, 2017, published: “Ortho Dermatologics Announces US FDA Filing Acceptance For IDP-121 Acne …” on January 12, 2018. More interesting news about Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were released by: and their article: “Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons” published on January 11, 2018 as well as‘s news article titled: “Valeant: Positive Catalysts Kick Off New Year” with publication date: January 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.